Shorts say: The phase III study of vosaroxin in acute myeloid leukemia will fail.
6. Synta Pharmaceuticals (SNTA)Short interest: 27% of float ^NBI data by YCharts
Shorts say: Synta designed the ongoing phase III lung cancer study of ganetespib around dubious, data-mined patient subgroup data. Like nearly all of these stories, the ending is tragic. 5. MannKind (MNKD) Short interest: 29% of float ^NBI data by YCharts
Shorts say: Inhaled insulin? Really? Bwhahahaha!